trivalent split influenza vaccine

BIOLOGICAL3 trials

Sponsors

Novartis, Universitaire Ziekenhuizen KU Leuven, Jiangsu Province Centers for Disease Control and Prevention

Conditions

COVID-19HemodialysisRenal TransplantationSeasonal InfluenzaVaccine

Phase 3

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

CompletedNCT00498303

NovartisSeasonal Influenza, Vaccine

Start: 2007-06-30Target: 120Updated: 2008-04-22

Phase 4

Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients

CompletedNCT00776750

Universitaire Ziekenhuizen KU LeuvenHemodialysis, Renal Transplantation

Start: 2003-09-30End: 2004-05-31Updated: 2008-10-21

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

CompletedNCT04833101

Jiangsu Province Centers for Disease Control and PreventionCOVID-19

Start: 2021-04-07End: 2022-03-04Updated: 2022-04-06

Related Papers

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial

PLoS Medicine2022-05-2644 citations